LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Tech-Driven Platform Celeris Therapeutics leverages an AI-driven platform, CelerisTx One™, to design proximity-inducing compounds for protein degradation, offering a cutting-edge solution for unmet needs in CNS and oncology markets.

Strategic Collaborations The company's partnership with Boehringer Ingelheim highlights its potential for collaboration with major pharmaceutical firms, opening avenues for joint drug development and licensing opportunities.

Targeted Disease Areas Focus on neurology and oncology signifies opportunities to tailor solutions for clients seeking innovative treatments in these high-growth, research-intensive sectors.

Growing Scientific Leadership Recent appointments of experienced executives such as a new VP of Drug Discovery and a Board Director with AI and biotech expertise suggest expanding scientific and strategic capacity that can facilitate enterprise scale-up.

Funding and Market Position With EUR 18 million in committed venture capital and a developing pipeline, Celeris is positioned to attract further investment from pharma companies looking for innovative biotech solutions with high scientific potential.

Celeris Therapeutics Tech Stack

Celeris Therapeutics uses 8 technology products and services including Vue.js, particles.js, scikit-learn, and more. Explore Celeris Therapeutics's tech stack below.

  • Vue.js
    Javascript Frameworks
  • particles.js
    Javascript Graphics
  • scikit-learn
    Machine Learning
  • Kaggle
    Machine Learning
  • TypeScript
    Programming Languages
  • Linux
    Programming Languages
  • PHP
    Programming Languages
  • YouTube
    Video Players

Media & News

Celeris Therapeutics's Email Address Formats

Celeris Therapeutics uses at least 1 format(s):
Celeris Therapeutics Email FormatsExamplePercentage
F.Last@celeristx.comJ.Doe@celeristx.com
50%
F.Last@celeristx.comJ.Doe@celeristx.com
50%

Frequently Asked Questions

Where is Celeris Therapeutics's headquarters located?

Minus sign iconPlus sign iconCeleris Therapeutics's main headquarters is located at Menlo Park, California 94025 United States. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is Celeris Therapeutics's official website and social media links?

Minus sign iconPlus sign iconCeleris Therapeutics's official website is celeristx.com and has social profiles on LinkedInCrunchbase.

What is Celeris Therapeutics's NAICS code?

Minus sign iconPlus sign iconCeleris Therapeutics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Celeris Therapeutics have currently?

Minus sign iconPlus sign iconAs of March 2026, Celeris Therapeutics has approximately 1 employees across 3 continents, including EuropeAsiaNorth America. Key team members include : H. T.. Explore Celeris Therapeutics's employee directory with LeadIQ.

What industry does Celeris Therapeutics belong to?

Minus sign iconPlus sign iconCeleris Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Celeris Therapeutics use?

Minus sign iconPlus sign iconCeleris Therapeutics's tech stack includes Vue.jsparticles.jsscikit-learnKaggleTypeScriptLinuxPHPYouTube.

What is Celeris Therapeutics's email format?

Minus sign iconPlus sign iconCeleris Therapeutics's email format typically follows the pattern of F.Last@celeristx.com. Find more Celeris Therapeutics email formats with LeadIQ.

How much funding has Celeris Therapeutics raised to date?

Minus sign iconPlus sign icon As of March 2026, Celeris Therapeutics has raised $9.8M in funding. The last funding round occurred on Oct 19, 2022 for $9.8M.

When was Celeris Therapeutics founded?

Minus sign iconPlus sign iconCeleris Therapeutics was founded in 2021.

Celeris Therapeutics

Pharmaceutical ManufacturingCalifornia, United States0-1 Employees

Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (CelerisTx One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices.

CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop therapeutics with pharmaceutical and biotech companies. 

CelerisTx has so far attracted a total of EUR 18 million in committed capital from venture capital funds, which include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42 and longevitytech.fund.

#targetedproteindegradation #degrader #ubiquitinproteasomesystem #machinelearning #CelerisOne #proximityinducingcompounds #PICs

Section iconCompany Overview

Headquarters
Menlo Park, California 94025 United States
Website
celeristx.com
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2021
Employees
0-1

Section iconMedia & News

Section iconFunding & Financials

  • $9.8M

    Celeris Therapeutics has raised a total of $9.8M of funding over 5 rounds. Their latest funding round was raised on Oct 19, 2022 in the amount of $9.8M.

  • $1M

    Celeris Therapeutics's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $9.8M

    Celeris Therapeutics has raised a total of $9.8M of funding over 5 rounds. Their latest funding round was raised on Oct 19, 2022 in the amount of $9.8M.

  • $1M

    Celeris Therapeutics's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    H. T.
    Phone icon
    Mobile Phone

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.